Finasteride Inhibits Human Prostate Cancer Cell Invasion Through MMP2 And MMP9 Downregulation

The study found that finasteride, a 5-alpha-reductase inhibitor, potentially reduced tumor aggressiveness and invasion in prostate cancer by downregulating MMP2 and MMP9, enzymes involved in cancer cell invasion. However, the effectiveness of finasteride could vary based on the androgen responsiveness of the patient's prostate cells. Despite ongoing debates about the incidence of high-grade prostate cancer in patients treated with 5-ARIs, these findings suggested a possible benefit of finasteride in managing prostate cancer invasiveness.